TrialA Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Trial details
- Registry ID
- NCT00081809
- Phase
- Phase 2
AGEN
Agenus Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
5Trials in this database
10Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent LymphomaNCT00081809 | AGEN | Phase 2 | Completed | 2005-06Actual |
| RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerNCT03894215 | AGEN | Phase 2 | Terminated | 2025-03-26Actual |
| A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaNCT05529316 | AGEN | Phase 2 | Active not recruiting | 2028-02Estimated |
| A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerNCT05608044 | AGEN | Phase 2 | Active not recruiting | 2027-09Estimated |
| A Study of Botensilimab in Participants With Metastatic Pancreatic CancerNCT05630183 | AGEN | Phase 2 | Completed | 2026-01-05Actual |
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
Trial details
- Registry ID
- NCT03894215
- Phase
- Phase 2
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
Trial details
- Registry ID
- NCT05529316
- Phase
- Phase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Trial details
- Registry ID
- NCT05608044
- Phase
- Phase 2
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
Trial details
- Registry ID
- NCT05630183
- Phase
- Phase 2
Latest recorded trial changes
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
NCT05630183 · Agenus Inc.
Completion date type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Primary completion date
Recorded edit− Previous value
2025-12-05
+ Updated value
2026-01-05
Recruitment status
Recorded edit− Previous value
Active not recruiting
+ Updated value
Completed
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
NCT03894215 · Agenus Inc.
Participant count type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Enrollment · participant count
Recorded edit− Previous value
count: 212; type: ESTIMATED
+ Updated value
count: 211; type: ACTUAL
Completion date type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Primary completion date
Recorded edit− Previous value
2025-08
+ Updated value
2025-03-26
Recruitment status
Recorded edit− Previous value
Active not recruiting
+ Updated value
Terminated
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
NCT05529316 · Agenus Inc.
Enrollment · participant count
Recorded edit− Previous value
count: 174; type: ACTUAL
+ Updated value
count: 150; type: ACTUAL
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
NCT05630183 · Agenus Inc.
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Progression-free Survival as Assessed by Independent Central Review Committee (IRC)
+ Updated value
measure: Progression-free Survival as Assessed by Investigator
The saved outcome text may be shortened. Check the source for full wording.